The Cancer Immunotherapy Guidelines Oversight Committee oversees the development of new disease-specific guidelines and updates for existing guidelines that provide guidance on the appropriate treatment algorithms and recommended administration of FDA-approved cancer immunotherapies as well as mitigating and managing adverse event. The oversight committee maintains standards for the SITC Cancer Immunotherapy Guidelines Expert Panels to ensure the recommendations are unbiased, relevant and facilitate clinical decision-making leading to optimal patient care
SITC’s Cancer Immunotherapy Guidelines Webinars connect clinicians with leading experts in the field and provide education about the evidence- and consensus-based recommendations in the clinical practice guidelines
Members receive free access to download any of SITC's Cancer Immunotherapy Guidelines – Pocket Guides on any desktop or mobile device. Click here for more information about SITC Cancer Immunotherapy Guidelines and Pocket Guides
This guideline covers immunotherapy for the treatment of esophageal, GE junction, gastric, duodenal and distal small bowel, pancreaticobiliary, colorectal, and anal cancer. The manuscript, the latest in the ongoing series of SITC Cancer Immunotherapy Guidelines, is available now in the Journal for ImmunoTherapy of Cancer ( JITC ), the society’s open access, peer-reviewed online journal and a mobile version with interactive tools will be available in the SITC CPG Mobile App soon
Submission Guidelines Below are the guidelines for your abstract submission
Highlighting key information from SITC’s published guidelines, the SITC CPG Mobile App features evidence- and expert consensus-based recommendations on important aspects of immunotherapy treatment as well as interactive tools and companion educational resources
SITC is pleased to announce a new educational offering for the society’s clinical practice guidelines – SITC’s Cancer Immunotherapy Guidelines Mini Modules. Designed for practitioners with a desire to learn but with limited time, the Mini Modules offer important key takeaways from the evidence- and consensus-based recommendations from the SITC clinical practice guidelines. Each Mini Module is a bite-sized video roughly 10 minutes in length focused on a single topic. Featuring members of the Expert Panel who developed the clinical practice guideline, the Mini Modules and are available here for the following disease and topic areas: SITC Acute Leukemia CPG Mini Modules Antibody-Drug Conjugates CAR T Cell Therapy for ALL in Adults Sequencing Therapies SITC Breast Cancer CPG Mini Modules First-Line Treatment of Metastatic TNBC Toxicities and Adverse Events Neoadjuvant and adjuvant treatment SITC Hepatocellular Carcinoma CPG Mini Modules Front-Line Management for Advanced HCC IO-IO Therapy in Second-Line Treatment Immunotherapy for HCC with Child-Pugh B Cirrhosis SITC Immune Checkpoint Inhibitor-related Adverse Events CPG Mini Modules Autoimmune Disease Special Patient Populations Vaccines and Chronic irAEs SITC Immune Effector Cell-related Adverse Events CPG Mini Modules CRS and HLH ICANS Product-specific Toxicity SITC Lymphoma CPG Mini Modules Bispecifics CAR T Integration with Transplant SITC Multiple Myeloma CPG Mini Modules Antibody-Drug Conjugates CAR T and Bispecifics Monoclonal Antibodies SITC Renal Cell Carcinoma CPG Mini Modules Management of ccRCC with Large Metastatic Burden Management of Toxicities Regimens for Challenging Patient Populations SITC Urothelial Cancer CPG Mini Modules Immune Irritability and Management of irAEs Management of High-Risk NMIBC Treatment of Unresectable Bladder Cancer SITC Head and Neck Squamous Cell Carcinoma CPG Mini Modules Treatment Strategies for Recurrent/Metastatic HNSCC Management of Pseudoprogression versus Unresponsive Disease Immunotherapy Combinations for Oligometastatic Disease March 16, 2022
Presented by the Arab Medical Association Against Cancer and the Algerian Society of Medical Oncology in collaboration with the Society for Immunotherapy of Cancer The 17th Pan Arab Cancer Congress (PACC), to be held on April 20-22, 2017, will explore the experiences and case studies of cancer management in the 22 Arabic countries, compare medical practices to local and global guidelines and offer networking opportunities for oncology clinicians and others involved in the cancer field. New this year, SITC is organizing an immunotherapy session to provide oncology practitioners with an understanding of the mechanisms of action of immunotherapy agents, discuss current clinical applications for melanoma and lung cancers, and introduce current and emerging treatment methods for additional disease states
04-21-2017 Algiers
Join
Renew
Member Directory
My Profile
Email Sign-up
Volunteer
Support SITC
Contact Us